G
Garson Tsang
Researcher at Plexxikon
Publications - 10
Citations - 3020
Garson Tsang is an academic researcher from Plexxikon. The author has contributed to research in topics: Vemurafenib & MAPK/ERK pathway. The author has an hindex of 7, co-authored 10 publications receiving 2493 citations.
Papers
More filters
Journal ArticleDOI
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF -mutant melanoma
Gideon Bollag,Peter Hirth,James Tsai,Jiazhong Zhang,Prabha N. Ibrahim,Hanna Cho,Wayne Spevak,Chao Zhang,Ying Zhang,Gaston Habets,Elizabeth A. Burton,Bernice Wong,Garson Tsang,Brian L. West,Ben Powell,Rafe Shellooe,Adhirai Marimuthu,Hoa Nguyen,Kam Y. J. Zhang,Dean R. Artis,Joseph Schlessinger,Fei Su,Brian Higgins,Raman Mahadevan Iyer,Kurt D'Andrea,Astrid Koehler,Michael Stumm,Paul S. Lin,Richard J. Lee,Joseph F. Grippo,Igor Puzanov,Kevin B. Kim,Antoni Ribas,Grant A. McArthur,Jeffrey A. Sosman,Paul B. Chapman,Keith T. Flaherty,Xiaowei Xu,Katherine L. Nathanson,K. B. Nolop +39 more
TL;DR: The structure-guided discovery of PLX4032 (RG7204), a potent inhibitor of oncogenic B-RAF kinase activity, and a remarkably high 81% response rate in metastatic melanoma patients treated at an oral dose of 960 mg twice daily are described, demonstrating that BRAF-mutant melanomas are highly dependent on B- RAF kinases activity.
Journal ArticleDOI
Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.
William D. Tap,Zev A. Wainberg,Stephen P. Anthony,Prabha N. Ibrahim,Chao Zhang,John H. Healey,Bartosz Chmielowski,Arthur P Staddon,Allen Lee Cohn,Geoffrey I. Shapiro,Vicki L. Keedy,Arun S. Singh,Igor Puzanov,Eunice L. Kwak,Andrew J. Wagner,Daniel D. Von Hoff,Glen J. Weiss,Ramesh K. Ramanathan,Jiazhong Zhang,Gaston Habets,Ying Zhang,Elizabeth A. Burton,Gary Conard Visor,Laura Sanftner,Paul Severson,Hoa Nguyen,Marie J Kim,Adhirai Marimuthu,Garson Tsang,Rafe Shellooe,Carolyn Gee,Brian L. West,Peter Hirth,K. B. Nolop,Matt van de Rijn,Henry H. Hsu,Charles Peterfy,Paul S. Lin,Sandra Tong-Starksen,Gideon Bollag +39 more
TL;DR: Treating tenosynovial giant-cell tumors with PLX3397 resulted in a prolonged regression in tumor volume in most patients, and the most common adverse events included fatigue, change in hair color, nausea, dysgeusia, and periorbital edema.
Journal ArticleDOI
Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer's disease model.
Elizabeth E. Spangenberg,Paul Severson,Lindsay A. Hohsfield,Joshua D. Crapser,Jiazhong Zhang,Elizabeth A. Burton,Ying Zhang,Wayne Spevak,Jack Lin,Nicole Y. Phan,Gaston Habets,Andrey Rymar,Garson Tsang,Jason Walters,Marika Nespi,Parmveer Singh,Stephanie Broome,Prabha N. Ibrahim,Chao Zhang,Gideon Bollag,Brian L. West,Kim N. Green +21 more
TL;DR: It is found that microglial depletion in a mouse model of Alzheimer’s disease impairs plaque formation and that Aβ-induced changes in neuronal gene expression are microglia-mediated.
Journal ArticleDOI
RAF inhibitors that evade paradoxical MAPK pathway activation
Chao Zhang,Wayne Spevak,Ying Zhang,Elizabeth A. Burton,Yan Ma,Gaston Habets,Jiazhong Zhang,Jack Lin,Todd Ewing,Bernice Matusow,Garson Tsang,Adhirai Marimuthu,Hanna Cho,Guoxian Wu,Weiru Wang,D. Fong,Hoa Nguyen,Songyuan Shi,Womack Patrick,Marika Nespi,Rafe Shellooe,Heidi Carias,Ben Powell,Emily Light,Laura Sanftner,Jason Walters,James Tsai,Brian L. West,Gary Conard Visor,Hamid Rezaei,Paul S. Lin,K. B. Nolop,Prabha N. Ibrahim,Peter Hirth,Gideon Bollag +34 more
TL;DR: Next-generation RAF inhibitors are identified (dubbed ‘paradox breakers’) that suppress mutant BRAF cells without activating the MAPK pathway in cells bearing upstream activation, a concept currently undergoing human clinical evaluation with PLX8394.
Journal ArticleDOI
Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 “Gatekeeper” F691L Mutation with PLX3397
Catherine C. Smith,Chao Zhang,Kimberly C. Lin,Elisabeth A. Lasater,Ying Zhang,Evan Massi,Lauren E. Damon,Matthew Pendleton,Ali Bashir,Robert Sebra,Alexander E. Perl,Andrew Kasarskis,Rafe Shellooe,Garson Tsang,Heidi Carias,Ben Powell,Elizabeth A. Burton,Bernice Matusow,Jiazhong Zhang,Wayne Spevak,Prabha N. Ibrahim,Mai H. Le,Henry Hsu,Gaston Habets,Brian L. West,Gideon Bollag,Neil P. Shah +26 more
TL;DR: The first cocrystal structure of FLT3 with the TKI quizart inib is reported, which demonstrates that quizartinib binding relies on essential edge-to-face aromatic interactions with the gatekeeper F691 residue, and F830 within the highly conserved Asp-Phe-Gly motif in the activation loop.